Illumina, Inc. (NASDAQ:ILMN) Stake Increased by Brown Advisory Inc.

Brown Advisory Inc. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 52.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,909,228 shares of the life sciences company's stock after purchasing an additional 996,589 shares during the quarter. Brown Advisory Inc. owned 1.84% of Illumina worth $230,818,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ILMN. Capital World Investors raised its position in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares during the period. Norges Bank acquired a new position in Illumina during the 4th quarter valued at approximately $228,714,000. Bessemer Group Inc. grew its stake in Illumina by 32,837.5% during the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock worth $180,152,000 after buying an additional 1,344,038 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Illumina by 2,057.5% in the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock worth $73,174,000 after buying an additional 879,533 shares during the period. Finally, Pictet Asset Management Holding SA increased its position in Illumina by 245.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company's stock worth $158,011,000 after buying an additional 840,423 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Ankur Dhingra acquired 6,100 shares of Illumina stock in a transaction on Monday, May 12th. The stock was bought at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the purchase, the chief financial officer owned 24,906 shares of the company's stock, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.60% of the company's stock.

Illumina Price Performance

Shares of NASDAQ ILMN traded down $0.80 during midday trading on Friday, reaching $99.25. The company's stock had a trading volume of 1,998,677 shares, compared to its average volume of 2,151,831. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a market cap of $15.71 billion, a price-to-earnings ratio of -16.35, a price-to-earnings-growth ratio of 1.96 and a beta of 1.36. The company has a 50 day moving average price of $87.18 and a 200 day moving average price of $96.48. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm's revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.98 earnings per share. On average, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ILMN shares. Barclays restated an "underweight" rating and set a $85.00 price target (up previously from $77.00) on shares of Illumina in a research report on Tuesday, June 24th. Citigroup cut shares of Illumina from a "hold" rating to a "strong sell" rating and decreased their target price for the stock from $85.00 to $80.00 in a research report on Wednesday. JPMorgan Chase & Co. cut their price target on Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Morgan Stanley decreased their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Finally, Canaccord Genuity Group raised their target price on Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Illumina currently has a consensus rating of "Hold" and a consensus price target of $125.11.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.